S. 316: Preserve Access to Affordable Generics Act
Before you vote › Federal bills
S. 316: Preserve Access to Affordable Generics Act
110th Congress · introduced 2007-01-17 · Commerce · Latest: Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights. Hearings held.
federal
Follow this bill, step by step
- Where it came from: introduced 2007-01-17 · official record
- Who proposed it: Sen. Kohl, Herb [D-WI] · what a sponsor is
- What happened next: no floor votes in our records yet. Why?
- Where it stands now: Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights. Hearings held. Not final yet: this can still change. We check for updates every day.
- If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.
Official title
Preserve Access to Affordable Generics Act
Plain summary
(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.) Preserve Access to Affordable Generics Act - Amends the Clayton Act to make it unlawful for a person, in connection with the sale of a drug product, to be a party to any agreement resolving or settling a patent infringement claim in which: (1) an abbreviated new drug (generic) application filer receives anything of value; and (2) such filer agrees not to research, develop, manufacture, market, or sell the generic product for any period. Excludes a resolution or settlement that includes no more than the right to market the generic product prior to the expiration of the patent. Amends the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to set forth additional filing requirements related to agreements between a brand name drug company and a generic drug applicant. Requires the Chief Executive Officer or the company official responsible for negotiating any agreement to file a certification that materials filed with respect to such agreements: (1) are complete, final, and exclusive; (2) include any ancillary agreements that are contingent upon, provide a contingent condition for, or are otherwise related to, the agreement; and (3) include written descriptions of any relevant oral agreements, representations, commitments, or promises between the parties that have not been reduced to writing. Amends the Federal Food, Drug, and Cosmetic Act to provide that forfeiture of the 180-day exclusivity period for the marketing of a generic drug occurs if there is a final decision of the Federal Trade Commission (FTC) or the court that an agreement has violated this Act. Requires the FTC to study the prevalence of anticompetitive agreements in the pharmaceutical industry and their impact. Requires the Attorney General or FTC to consider whether any additional enforcement action is necessary. Authorizes appropriations.
Congressional Research Service summary (Reported to Senate without amendment), quoted unchanged (nonpartisan). Read the source.
What a vote does
A “Yea” vote
If it passes both chambers and is signed, it becomes law.
A “Nay” vote
If it is not passed, current law stays as it is.
PSI Sci description of the legislative step (not an opinion).
What does this mean? (plain words)
Official text
Preserve Access to Affordable Generics Act
Source: Congressional Research Service summary (Reported to Senate without amendment)
AI explanation – may be wrong, check the official text
No AI explanation yet. It takes up to a minute to write and is then saved for everyone.
Limited to a few requests an hour per person.
The strongest published arguments
Arguments for (supporters)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Arguments against (opponents)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Alternatives
Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.
How did my representative vote? · This bill's floor votes
Officials and money
Sponsor: Sen. Kohl, Herb [D-WI] · 10 cosponsors
Cost estimate: No cost estimate published yet.
Cosponsors on this site
Chuck Grassley (R-IA), Charles E. Schumer (D-NY), Richard J. Durbin (D-IL), Amy Klobuchar (D-MN)
No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.
Words on this page, explained (2)
- Appropriation
- Money a legislature sets aside by law for a specific purpose. Government agencies may spend public money only as it has been appropriated.
- Resolution
- A formal statement or decision by a legislative body. Simple resolutions often only express an opinion or set rules for one chamber; they do not become law.
Plain meanings written from linked sources. All words.
Sources
- Congressional Research Service summary (Reported to Senate without amendment)
- Congress.gov
- Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-110s316.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/110/s>
Record fed-us-cong110-s316 · catalog fed-us-congress-bills-cong110 · updated 2026-11-15 by psicol fed-bills-cong110